Thomas Smith
Stock Analyst at Leerink Partners
(1.41)
# 2,495
Out of 4,412 analysts
58
Total ratings
31.34%
Success rate
n/a
Average return
Main Sectors:
Top Industries:
27 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $21.03 | +85.45% | 1 | Apr 23, 2024 | |
| ALPN Alpine Immune Sciences | Downgrades: Market Perform | $42 → $65 | $64.56 | +0.68% | 2 | Apr 12, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $4.06 | +540.39% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $10 | $8.10 | +23.46% | 2 | Feb 21, 2024 | |
| ABVX Abivax | Initiates: Outperform | $20 | $15.78 | +26.74% | 1 | Nov 14, 2023 | |
| MORF Morphic Holding | Maintains: Outperform | $45 → $56 | $28.07 | +99.50% | 1 | Mar 8, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $372.80 | +16.68% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $27.55 | +30.67% | 1 | Feb 28, 2023 | |
| EQ Equillium | Maintains: Outperform | $12 → $7 | $1.71 | +309.36% | 3 | Feb 8, 2023 | |
| CNTB Connect Biopharma Holdings | Maintains: Outperform | $9 → $7 | $1.34 | +422.39% | 4 | Feb 8, 2023 | |
| IMVT Immunovant | Maintains: Outperform | $14 → $21 | $27.17 | -22.71% | 3 | Feb 6, 2023 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $40 → $45 | $12.88 | +249.38% | 2 | Jan 9, 2023 | |
| TRVI Trevi Therapeutics | Initiates: Outperform | $6 | $2.78 | +115.83% | 1 | Nov 22, 2022 | |
| LABP Landos Biopharma | Maintains: Market Perform | $30 → $20 | $22.31 | -10.35% | 4 | Nov 11, 2022 | |
| MNKD MannKind | Maintains: Outperform | $5 → $6 | $4.23 | +41.84% | 2 | Nov 9, 2022 | |
| IMUX Immunic | Downgrades: Market Perform | $9 → $5 | $1.22 | +309.84% | 3 | Oct 21, 2022 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $17 | $42.49 | -59.99% | 1 | Aug 25, 2022 | |
| CLDX Celldex Therapeutics | Maintains: Outperform | $68 → $64 | $36.30 | +76.31% | 2 | Aug 9, 2022 | |
| PRTC PureTech Health | Maintains: Outperform | $66 → $70 | $28.50 | +145.61% | 5 | Aug 9, 2022 | |
| ETNB 89bio | Maintains: Outperform | $50 → $29 | $8.26 | +251.09% | 3 | Jul 11, 2022 | |
| ELDN Eledon Pharmaceuticals | Maintains: Outperform | $33 → $26 | $2.06 | +1,162.14% | 3 | Jun 1, 2022 | |
| ALLK Allakos | Maintains: Market Perform | $13 → $12 | $1.02 | +1,076.47% | 3 | May 12, 2022 | |
| VKTX Viking Therapeutics | Maintains: Outperform | $18 → $12 | $74.31 | -83.85% | 1 | Apr 28, 2022 | |
| GNFT Genfit | Maintains: Outperform | $15 → $10 | $3.49 | +186.53% | 2 | Apr 11, 2022 | |
| GLTO Galecto | Maintains: Outperform | n/a | $0.70 | - | 1 | Mar 16, 2021 | |
| ACRS Aclaris Therapeutics | Maintains: Outperform | n/a | $1.20 | - | 2 | Mar 4, 2021 | |
| KROS Keros Therapeutics | Initiates: Outperform | n/a | $57.86 | - | 1 | May 4, 2020 |
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $21.03
Upside: +85.45%
Alpine Immune Sciences
Apr 12, 2024
Downgrades: Market Perform
Price Target: $42 → $65
Current: $64.56
Upside: +0.68%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $4.06
Upside: +540.39%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $10
Current: $8.10
Upside: +23.46%
Abivax
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $15.78
Upside: +26.74%
Morphic Holding
Mar 8, 2023
Maintains: Outperform
Price Target: $45 → $56
Current: $28.07
Upside: +99.50%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $372.80
Upside: +16.68%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $27.55
Upside: +30.67%
Equillium
Feb 8, 2023
Maintains: Outperform
Price Target: $12 → $7
Current: $1.71
Upside: +309.36%
Connect Biopharma Holdings
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.34
Upside: +422.39%
Immunovant
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $27.17
Upside: -22.71%
Viridian Therapeutics
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $12.88
Upside: +249.38%
Trevi Therapeutics
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $2.78
Upside: +115.83%
Landos Biopharma
Nov 11, 2022
Maintains: Market Perform
Price Target: $30 → $20
Current: $22.31
Upside: -10.35%
MannKind
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $4.23
Upside: +41.84%
Immunic
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $1.22
Upside: +309.84%
MoonLake Immunotherapeutics
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $42.49
Upside: -59.99%
Celldex Therapeutics
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $36.30
Upside: +76.31%
PureTech Health
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $28.50
Upside: +145.61%
89bio
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $8.26
Upside: +251.09%
Eledon Pharmaceuticals
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.06
Upside: +1,162.14%
Allakos
May 12, 2022
Maintains: Market Perform
Price Target: $13 → $12
Current: $1.02
Upside: +1,076.47%
Viking Therapeutics
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $74.31
Upside: -83.85%
Genfit
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.49
Upside: +186.53%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: n/a
Current: $0.70
Upside: -
Aclaris Therapeutics
Mar 4, 2021
Maintains: Outperform
Price Target: n/a
Current: $1.20
Upside: -
Keros Therapeutics
May 4, 2020
Initiates: Outperform
Price Target: n/a
Current: $57.86
Upside: -